Highlights from the AAN and CMSC 2017 Annual Meetings

During the past few decades, advancements made in multiple sclerosis (MS) research have revolutionized the field. Thus far in 2017, the brisk pace has continued. The American Academy of Neurology (AAN) meeting in April 2017 in Boston, Massachusetts and the Consortium of MS Centers Conference (CMSC) in May 2017 in New Orleans, Louisiana were both […]

Read News Article

MSAA Receives Recognition and an Award for MS Conversations Blog and Changing Lives Monday to Sunday Video

The Multiple Sclerosis Association of America (MSAA) is proud to announce two exciting achievements! MSAA’s MS Conversations blog has been included in Medical News Today’s Best Multiple Sclerosis Blogs feature. Additionally, MSAA’s Changing Lives Monday to Sunday video has been selected as a Spring 2017 Digital Health Awards winner in the Bronze category! The 19th […]

Read News Article

The Multiple Sclerosis Association of America Publishes New Resources

The Multiple Sclerosis Association of America is pleased to announce three new resources for the multiple sclerosis (MS) community. These new publications are available free-of-charge as both printed and online versions on mymsaa.org. MSAA’s award-winning magazine, The Motivator, provides valuable information and support for individuals living with MS, their care partners, family members, and medical […]

Read News Article

FDA Approves myBETAapp and BETACONNECT Navigator

A new mobile and cloud-based health technology offered by Bayer has been approved by the United States Food and Drug Administration (FDA) for individuals taking Betaseron for relapsing-remitting MS. On May 30, 2017, Bayer announced the approval of myBETAapp™ and the BETACONNECT Navigator™. With this software, in conjunction with Bluetooth technology, individuals using the electronic […]

Read News Article

First Case of PML with Ocrevus is Reported

An individual with multiple sclerosis (MS) in Germany has developed progressive multifocal leukoencephalopathy (PML) following three years of treatment with Tysabri® (natalizumab) and one dose of Ocrevus™ (ocrelizumab). PML is a potentially fatal brain infection that can occur in people with a weakened immune system, which can result from taking an immunosuppressant. An increased risk […]

Read News Article

MS Conversations Recognized as One of the Best MS Blogs of 2017 by Healthline

The Multiple Sclerosis Association of America’s MS Conversations blog is honored to be named one of Healthline’s Best Multiple Sclerosis Blogs of 2017. MSAA is pleased to have received this award for the third consecutive year. Recently, Healthline chose 23 blogs that actively work to educate, inspire, and empower readers with frequent updates and high-quality […]

Read News Article

FDA Approves First Drug to Treat Two Forms of MS

On March 28, 2017, the United States Food and Drug Administration (FDA) announced the approval of Ocrevus™ (ocrelizumab) for the treatment of two types of multiple sclerosis (MS): relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This is the first time that a medication for MS has been approved for two types of the […]

Read News Article

Patient Access Network (PAN) Foundation and MSAA Launch Alliance to Support People Living with MS

The Patient Access Network (PAN) Foundation and Multiple Sclerosis Association of America (MSAA) today announced they are launching a new alliance to offer a broad range of support for people living with multiple sclerosis (MS). Working together, the PAN Foundation and MSAA will ensure that people living with multiple sclerosis have access to both financial […]

Read News Article